Jeil Pharm (002620) - Total Liabilities

Latest as of March 2026: ₩403.14 Billion KRW ≈ $273.20 Million USD

Based on the latest financial reports, Jeil Pharm (002620) has total liabilities worth ₩403.14 Billion KRW (≈ $273.20 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore 002620 net assets growth trend to track the company's year-over-year net asset growth rate.

Jeil Pharm - Total Liabilities Trend (2011–2025)

This chart illustrates how Jeil Pharm's total liabilities have evolved over time, based on quarterly financial data. See 002620 cash flow after capex ratio to measure how efficiently the company converts operating cash flow to free cash.

Jeil Pharm Competitors by Total Liabilities

The table below lists competitors of Jeil Pharm ranked by their total liabilities.

Company Country Total Liabilities
DOMESCO Medical Import Export JSC
VN:DMC
Vietnam ₫205.43 Billion
Alithya Group inc Class A
TO:ALYA
Canada CA$239.27 Million
Forum Markets, Incorporated
NASDAQ:FRMM
USA $39.27 Million
Super Dragon Technology Co Ltd
TW:9955
Taiwan NT$1.80 Billion
Inscobee
KO:006490
Korea ₩48.82 Billion
Brixton Metals Corporation
V:BBB
Canada CA$1.94 Million
IokCompany Co. Ltd
KQ:078860
Korea ₩15.25 Billion
Consolidated Construction Consortium Limited
NSE:CCCL
India Rs2.16 Billion

Liability Composition Analysis (2011–2025)

This chart breaks down Jeil Pharm's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Jeil Pharm stock valuation.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 1.22 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 1.26 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.46 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Jeil Pharm's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Jeil Pharm (2011–2025)

The table below shows the annual total liabilities of Jeil Pharm from 2011 to 2025.

Year Total Liabilities Change
2025-12-31 ₩407.55 Billion
≈ $276.19 Million
-10.04%
2024-12-31 ₩453.04 Billion
≈ $307.02 Million
-5.19%
2023-12-31 ₩477.81 Billion
≈ $323.81 Million
+7.16%
2022-12-31 ₩445.88 Billion
≈ $302.17 Million
+13.71%
2021-12-31 ₩392.11 Billion
≈ $265.73 Million
+1.03%
2020-12-31 ₩388.11 Billion
≈ $263.02 Million
+6.79%
2019-12-31 ₩363.44 Billion
≈ $246.30 Million
+9.96%
2018-12-31 ₩330.51 Billion
≈ $223.98 Million
+1117.39%
2017-12-31 ₩27.15 Billion
≈ $18.40 Million
-88.68%
2016-12-31 ₩239.91 Billion
≈ $162.58 Million
+17.73%
2015-12-31 ₩203.78 Billion
≈ $138.10 Million
+36.43%
2012-12-31 ₩149.36 Billion
≈ $101.22 Million
-2.21%
2011-12-31 ₩152.74 Billion
≈ $103.51 Million
--

About Jeil Pharm

KO:002620 Korea Drug Manufacturers - Specialty & Generic
Market Cap
$75.01 Million
₩110.68 Billion KRW
Market Cap Rank
#20241 Global
#1046 in Korea
Share Price
₩7210.00
Change (1 day)
+3.89%
52-Week Range
₩6290.00 - ₩9280.00
All Time High
₩92178.44
About

Jeil Pharma Holdings Inc manufactures and sells ingredients of drugs, incrementally modified drugs, and generic drugs in South Korea. The company offers active pharmaceutical ingredients in the areas of antibiotics, gastrointestinal, cardiovascular, neuropsychiatry, oncology, endocrinology, urology, antiviral, and antihistamines, as well as patch products. It also provides finished dosage forms i… Read more